Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859828 | 0.98 | TSHR (0.47) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL19025418 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL18856287 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL18723036 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL19025446 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL4582699 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL17676317 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL30522611 | 0.96 | PRSS1 (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28600923 | 0.94 | PRSS1 (0.50) | PRSS1PRSS2PRSS3TSHRCYP3A4 | |
| SCHEMBL3753776 | 0.94 | TSHR (0.51) | PRSS1PRSS2PRSS3TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2025-02-20 | — | — | US | disclosed |
| US-12090131-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2024-09-17 | — | — | US | disclosed |
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11491127-B2 | Therapeutic use of compounds | UCL BUSINESS PLC (GB) | 2022-11-08 | — | — | US | disclosed |
| US-11419839-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2022-08-23 | — | — | US | disclosed |
| EP-2737901-B1 | Therapeutic Use of Compounds | UCL BUSINESS LTD (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-20200268699-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-08-27 | — | — | US | disclosed |
| US-20200197344-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-06-25 | — | — | US | disclosed |
| EP-3636259-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-04-15 | — | — | EP | disclosed |
| US-10548866-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-2642990-B1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-2737901-A1 | Therapeutic Use of Compounds | UCL Business PLC (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2013-11-14 | — | — | US | disclosed |
| EP-2642990-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL Business Plc. (GB) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069790-A1 | THERAPEUTIC USE OF COMPOUNDS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | PRSS1 2107/4885PRSS2 3536/4885PRSS3 3073/4885 |
| US-20200268699-A1 | THERAPEUTIC USE OF COMPOUNDS | DEGS1, CYP11B1, SGMS1 | PRSS1 2298/4885PRSS2 3771/4885PRSS3 3199/4885 |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | BACE1, CPT1A, BCL6 | PRSS1 2579/4885PRSS2 4266/4885PRSS3 4334/4885 |
| US-10548866-B2 | Therapeutic use of compounds | BACE1, BCL6, BCL6B | PRSS1 2859/4885PRSS2 4252/4885PRSS3 4321/4885 |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | CYP11B1, SGMS1, PTGER1 | PRSS1 1724/4885PRSS2 3233/4885PRSS3 2963/4885 |
| US-12090131-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | PRSS1 2107/4885PRSS2 3536/4885PRSS3 3073/4885 |
| US-11419839-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | PRSS1 2107/4885PRSS2 3536/4885PRSS3 3073/4885 |
| US-11491127-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | PRSS1 2107/4885PRSS2 3536/4885PRSS3 3073/4885 |
| US-20200197344-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | PRSS1 2107/4885PRSS2 3536/4885PRSS3 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.